• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lava Therapeutics N.V. (NQ: LVTX )

    1.890 +0.020 (+1.07%)
    Streaming Delayed Price Updated: 3:57 PM EDT, Jul 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 53,151
    Open 1.850
    Bid (Size) 1.850 (16)
    Ask (Size) 2.020 (20)
    Prev. Close 1.870
    Today's Range 1.850 - 2.020
    52wk Range 1.131 - 6.470
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Announces Annual Meeting of Shareholders
    From LAVA Therapeutics N.V.
    Via GlobeNewswire

    Performance

    YTD
    +7.82%
    +7.82%
    1 Month
    -22.54%
    -22.54%
    3 Month
    -43.92%
    -43.92%
    6 Month
    +7.82%
    +7.82%
    1 Year
    -1.05%
    -1.05%

    More News

    Read More
    LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    What 5 Analyst Ratings Have To Say About LAVA Therapeutics
    Via Benzinga
    LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
    Via FinancialNewsMedia
    Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
    From FN Media Group LLC
    Via GlobeNewswire
    LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
    Via AB Newswire
    Topics Retirement
    Exposures Pension
    Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
    Via Benzinga
    Topics Government
    Exposures Political
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Dow Surges Over 100 Points; US GDP Growth Tops Estimates
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
    Via Benzinga
    LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.